Eton Pharmaceuticals Inc expected to post a loss of 4 cents a share - Earnings Preview

Eton Pharmaceuticals

05/08/2025 21:55

Eton Pharmaceuticals Inc ETON.OQ ETON.O is expected to  show a rise in quarterly revenue when it reports  results on August 7 for the period ending June 30 2025

The Deer Park Illinois-based  company is expected to report a 84.2% increase in revenue to $16.711 million from $9.07 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Eton Pharmaceuticals Inc is for a loss of 4 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Eton Pharmaceuticals Inc is $28.00, about 48.6% above its last closing price of $14.39

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
0.06
0.05
0.07
Beat
31.3
Dec. 31 2025
-0.01
0.00
-0.02
Missed
-500.6
Sep. 30 2024
-0.01
-0.01
0.03
Beat
400​
Jun. 30 2024
-0.07
-0.07
-0.12
Missed
-71.4
​​Mar. 31 2024
-0.07
-0.04
-0.03
Beat
33.3
Dec. 31 2023
-0.04
-0.04
-0.09
Missed
-125​
Sep. 30 2023
-0.10
-0.10
-0.02
Beat
80
Jun. 30 2023
-0.09
-0.09
0.15
Beat
266.7

This summary was machine generated August 5 at 20:55 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)